Why the study?
Does the combination of adrenomedullin and an endopeptidase inhibitor improve hemodynamic and renal parameters in sheep with experimental heart failure?
Does the combination of adrenomedullin and an endopeptidase inhibitor improve hemodynamic and renal parameters in sheep with experimental heart failure?
Cotreatment with adrenomedullin and an endopeptidase inhibitor provides synergistic hemodynamic and renal benefits in an experimental sheep model of heart failure.
No takes yet. Share an insight, caveat, or question.
Premature for clinical use in heart failure; extends synergistic benefits of adrenomedullin-endopeptidase inhibition to experimental models.
Rademaker et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: